Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis

BACKGROUND: For patients with advanced non-small cell lung carcinoma (NSCLC), immune checkpoint inhibitor (ICPI) and chemotherapy (chemo) ICPI represent two distinct first-line standard-of-care regimens without clear and established biomarkers to inform the optimal choice for individual patients. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Richard S P, Carbone, David P, Li, Gerald, Schrock, Alexa, Graf, Ryon P, Zhang, Liangliang, Murugesan, Karthikeyan, Ross, Jeffrey S, Tolba, Khaled, Sands, Jacob, Oxnard, Geoffrey R, Spigel, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853253/
https://www.ncbi.nlm.nih.gov/pubmed/36650021
http://dx.doi.org/10.1136/jitc-2022-005801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853253/
https://www.ncbi.nlm.nih.gov/pubmed/36650021
http://dx.doi.org/10.1136/jitc-2022-005801

Ejemplares similares